Studies have demonstrated that targeting this axis—through the inhibition of C-X-C Chemokine Receptor Type 4 (CXCR4) or TGF-β signaling—can remodel the tumor stroma, enhance CD8+ T cell infiltration, and improve the effectiveness of immune checkpoint blockades [144,145]. The gene discussed is CD8A; the disease is neoplasm.